公开(公告)号：US20170037366A1

公开(公告)日：2017-02-09

申请号：US15303520

申请日：2014-04-11

Applicant: Agency for Science, Technology and Research ,  Singapore Health Services Pte Ltd

Inventor： Mei Yee Vanessa DING ,  Boon Hwa Andre CHOO ,  Chui Ping Angela CHIN ,  Jodhbir Singh MEHTA ,  Gary PEH

IPC: C12N5/079 ,  C07K16/40 ,  C07K16/28

CPC classification number: C12N5/0621 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/40 ,  C07K2317/33

Abstract: This invention refers to an antibody or an antigen binding portion thereof, that binds specifically to human corneal endothelial cells (hCENCs), wherein the target of the monoclonal antibody, or antigen binding portion thereof, is essentially cell surface-expressed Peroxiredoxin-6 (Prdx6), as well as to methods for determining suitability of a cell sample for corneal transplantation, for quantitative enrichment of human corneal endothelial cells from a mixture of cells, and for isolating human corneal en dothelial cells from a mixture of cell.

Abstract translation: 本发明涉及与人角膜内皮细胞（hCENC）特异性结合的抗体或其抗原结合部分，其中单克隆抗体或其抗原结合部分的靶基本上是细胞表面表达的过氧化还原毒素-6（Prdx6） ），以及用于确定角膜移植的细胞样品的适合性的方法，用于从细胞混合物定量富集人角膜内皮细胞，以及从细胞混合物分离人角膜上皮细胞。

公开(公告)号：US20240132595A1

公开(公告)日：2024-04-25

申请号：US18275519

申请日：2022-01-28

Applicant: Agency for Science, Technology and Research

Inventor： Chui Ping Angela CHIN ,  Boon Hwa Andre CHOO ,  Wey Jia FONG ,  Mei Yee Vanessa DING

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00

CPC classification number: C07K16/2833 ,  A61K47/68031 ,  A61P35/00 ,  C07K2317/24 ,  C07K2317/565

Abstract: The invention relates to antigen-binding molecules that specifically bind to MHC Class I DLA-12 antigen. In one embodiment, the antigen-binding molecule is an antibody that specifically binds to canine MHC Class I DLA-12 antigen. Chimeric molecules of the antibody conjugated to another heterologous moiety are also provided. In one embodiment, the heterologous moiety is monomethyl auristatin E (MMAE). A method of inhibiting cancer using the antibody or the chimeric molecule thereof is also provided. In another embodiment, the antibody-MMAE conjugate suppresses tumour development in a murine model of B cell lymphoma.